Sequential drug delivery to modulate macrophage behavior and enhance implant integration

Erin M O'Brien; Gregory E Risser; Kara L Spiller

doi:10.1016/j.addr.2019.05.005

Sequential drug delivery to modulate macrophage behavior and enhance implant integration

Adv Drug Deliv Rev. 2019 Sep-Oct:149-150:85-94. doi: 10.1016/j.addr.2019.05.005. Epub 2019 May 16.

Authors

Erin M O'Brien¹, Gregory E Risser¹, Kara L Spiller²

Affiliations

¹ Biomaterials and Regenerative Medicine Laboratory, School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA, United States.
² Biomaterials and Regenerative Medicine Laboratory, School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA, United States. Electronic address: spiller@drexel.edu.

Abstract

Macrophages are major upstream regulators of the inflammatory response to implanted biomaterials. Sequential functions of distinct macrophage phenotypes are essential to the normal tissue repair process, which ideally results in vascularization and integration of implants. Improper timing of M1 or M2 macrophage activation results in dysfunctional healing in the form of chronic inflammation or fibrous encapsulation of the implant. Thus, biphasic drug delivery systems that modulate macrophage behavior are an appealing approach to promoting implant integration. In this review, we describe the timing and roles of macrophage phenotypes in healing, then highlight current drug delivery systems designed to sequentially modulate macrophage behavior.

Keywords: Angiogenesis; Implant integration; Macrophage.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Animals
Drug Delivery Systems*
Humans
Inflammation / metabolism
Macrophages / drug effects*
Macrophages / metabolism
Phenotype
Prostheses and Implants*

Grants and funding

R01 HL130037/HL/NHLBI NIH HHS/United States